• The Academy has a profound duty to its members, the larger medical community and the public to ensure the integrity of all of its scientific, educational, advocacy and consumer information activities and materials. Thus each Academy Trustee, Secretary, committee Chair, committee member, taskforce chair, taskforce member, councilor, and representative to other organizations (“Academy Leader”), as well as the Academy staff and those responsible for organizing and presenting CME activities must disclose interactions with Companies and manage conflicts of interest or the appearance of conflicts of interest that affect this integrity. Where such conflicts or perceived conflicts exist, they must be appropriately and fully disclosed and resolved.

    All contributors to Academy educational and leadership activities must disclose all financial relationships (defined below) to the Academy annually. The ACCME requires the Academy to disclose the following to participants prior to the activity:

    • All financial relationships with Commercial Companies that contributors and their immediate family have had within the previous 12 months. A commercial company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
    • Meeting presenters, authors, contributors or reviewers who report they have no known financial relationships to disclose.

    The Academy will request disclosure information from meeting presenters, authors, contributors or reviewers, committee members, Board of Trustees, and others involved in Academy leadership activities (“Contributors”) annually. Disclosure information will be kept on file and used during the calendar year in which it was collected for all Academy activities. Updates to the disclosure information file should be made whenever there is a change. At the time of submission of a Journal article or materials for an educational activity or nomination to a leadership position, each Contributor should specifically review his/her statement on file and notify the Academy of any changes to his/her financial disclosures. These requirements apply to relationships that are in place at the time of or were in place 12 months preceding the presentation, publication submission, or nomination to a leadership position. Any financial relationship that may constitute a conflict of interest will be resolved prior to the delivery of the activity.

    Financial Relationship Disclosure

    For purposes of this disclosure, a known financial relationship is defined as any financial gain or expectancy of financial gain brought to the Contributor or the Contributor’s immediate family (defined as spouse, domestic partner, parent, child or spouse of child, or sibling or spouse of sibling of the Contributor) by:

    • Direct or indirect compensation;
    • Ownership of stock in the producing company;
    • Stock options and/or warrants in the producing company, even if they have not been exercised or they are not currently exercisable;
    • Financial support or funding to the investigator, including research support from government agencies (e.g., NIH), device manufacturers, and\or pharmaceutical companies; or
    • Involvement with any for-profit corporation that is likely to become involved in activities directly impacting the Academy where the Contributor or the Contributor’s family is a director or recipient of a grant from said entity, including consultant fees, honoraria, and funded travel.

    Description of Financial Interests

    Consultant / Advisor C Consultant fee, paid advisory boards or fees for attending a meeting.
    Employee E Employed by or received a W2 from a commercial company.
    Lecture Fees L Lecture fees or honoraria, travel fees or reimbursements when speaking at the invitation of a commercial company.
    Equity / Stock Owner O Equity ownership/stock options in publicly or privately traded firms, excluding mutual funds.
    Patents / Royalty P Patents and/or royalties for intellectual property.
    Grant Support S Grant support or other financial support to the investigator from all sources, including research support from government agencies (e.g., NIH), foundations, device manufacturers, and\or pharmaceutical companies.

    Secretary for Annual Meeting

    Name Disclosure
    Maria M Aaron MD None

    Annual Meeting Program Committee

    The Annual Meeting Program Committee is responsible for the Academy's annual meeting Scientific Program, including Instruction Courses, Symposia, the Spotlight on Cataract, Scientific Papers/ePosters and Videos. Each subcommittee has five - ten reviewers who grade the instruction courses and paper/e-poster abstracts as well as three subcommittee members who review the grades, then select the courses and abstracts for presentation.

    Associate Secretary for the Annual Meeting Program Disclosure
    Bennie H Jeng MD EyeGate Pharmaceuticals Inc.: O; GlaxoSmithKline: C; Kedrion: C; Merck & Co., Inc.: C; Oyster point: C; Sanofi: C
    Annual Meeting Program Committee
    Nicole R Fram MD Alcon Laboratories, Inc.: C,L; Allergan: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,O,L; Dompé: C,L; Johnson & Johnson Vision: C; MicroSurgical Technology: L; Novartis Pharma AG: L; Ocular Science: O; Ocular Therapeutix: C,L
    Jessica B Ciralsky MD Bruder Healthcare Company: C; Johnson & Johnson Vision: C; Novartis, Alcon Pharmaceuticals: C
    Steven J Gedde MD None
    Andrew G Lee MD None
    Julian D. Perry, MD None
    Martha P Schatz MD None
    Elizabeth Yeu MD Alcon Laboratories, Inc.: C,L; Allergan: C,L; ArcScan: C; Bausch + Lomb: C; Bausch Lomb: C; Bio-Tissue, Inc.: C,L; Carl Zeiss Meditec: C,L; Glaukos Corporation: C,L; nnovation Labs: O; iOptics: C,S; Johnson & Johnson Vision: C,L; Kala: C,S; Katena Products, Inc: C; Melt: C,O; Modernizing Medicine: O; Novartis, Alcon Pharmaceuticals: C; Ocular Science: C,O; OcuSoft: C; Omeros: L; ScienceBased Health: C; Sight Sciences: C; Sun Ophthalmics: L; Surface: C; Tarsus: C,O; TearLab: C; TearScience: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S
    Sharon D Solomon MD None

    Subcommittee for: Cataract

    Chair Disclosure
    Nicole R Fram MD Alcon Laboratories, Inc.: C,L; Allergan: C; Beaver-Visitec International, Inc.: L; CorneaGen: C,O,L; Dompé: C,L; Johnson & Johnson Vision: C; MicroSurgical Technology: L; Novartis Pharma AG: L; Ocular Science: O; Ocular Therapeutix: C,L
    Subcommittee Members
    Surendra Basti MBBS Bausch + Lomb: C; Johnson & Johnson Vision: C
    Sathish Srinivasan MBBS Alcon Laboratories, Inc.: C; DORC International, bv/Dutch Ophthalmic, USA: C; Medicontur: C; Scope Ophthalmics: C; THEA: L; Zeiss: C
    Subcommittee Reviewers
    Brandon Ayres MD Alcon Laboratories, Inc.: C,L; Allergan: C,L; Bausch+Lomb: L; Carl Zeiss Inc: C; CorneaGen: C; Dompe: C,L; Glaukos Corporation: C; New World Medical Inc: C; Novartis, Alcon Pharmaceuticals: C; omeros: C; Sun Ophthalmics: C,L; Tear Lab: C
    Kourtney A Houser MD Alcon: L; Bausch and Lomb: C; Novartis, Alcon Pharmaceuticals: C
    Sumitra S Khandelwal MD Alcon Laboratories, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Dompe: C; Kala: C; Ocular Therapeutix: C; Omeros Corporation: C
    Jeremy Z Kieval MD Alcon Laboratories, Inc.: C; Dompe: C; Johnson & Johnson: C,L; Kala: C,L; Novartis Pharma AG: C; Ocular Therapeutix: C; Sun Ophthalmics: C; Takeda: C,L; Tarsus: C
    Steven M Naids MD Allergan, Inc.: C; Bausch + Lomb: L; Eyevance: C

    Subcommittee for: Cornea, External Disease

    Chair Disclosure
    Jessica B Ciralsky MD Bruder Healthcare Company: C; Johnson & Johnson Vision: C; Novartis, Alcon Pharmaceuticals: C
    Subcommittee Members
    Jennifer Y Li MD None
    Elmer Y Tu MD Daiichi Sankyo: C; Dompe: C; Eversight: E,S; Eye Bank Association of America: S; GlaxoSmithKline: C; Oyster Point: C; Santen, Inc.: C
    Subcommittee Reviewers
    Vatinee Y Bunya MD Bausch + Lomb: S
    Asim V Farooq MD GlaxoSmithKline: C
    Marjan Farid MD Allergan: C; Bausch + Lomb: C; Bio-Tissue, Inc.: C; CorneaGen: C; Dompe: C; Johnson & Johnson Vision: C; KALA: C; Novartis, Alcon Pharmaceuticals: C; Sun Ophthalmics: C; Tarsus: C; zeiss: C
    Anat Galor MD Allergan: C; Dompe: C; Novaliq: C; Novartis Pharma AG: C; Shire: C
    Jennifer R Rose-Nussbaumer MD None

    Subcommittee for: Glaucoma

    Chair Disclosure
    Steven J Gedde MD None
    Members
    Paula Anne Newman-Casey MD Centers for Disease Control and Prevention: S; National Eye Institute: S
    Brian C Samuels MD PhD Heidelberg Engineering: S
    Subcommittee Reviewers
    Jenny Chen MD None
    John T Lind MD Heru: S; Nicox: S
    Catherine Q Sun MD National Eye Institute: S
    Sarah Van Tassel MD Abbvie: C; Aerie Pharmaceuticals, Inc.: C; Bausch + Lomb: C; Carl Zeiss Meditec: C; Equinox: C; New World Medical Inc: C
    Luis E Vazquez MD None

    Subcommittee for: Neuro-Ophthalmology, Electronic Health Records/Information Technology, Ethics, General Medical, Global Ophthalmology, Medical Education, Ophthalmic History and Vision Rehabilitation

    Chair Disclosure
    Andrew G Lee MD None
    Members
    John J Chen MD PHD Roche Diagnostics: C; UCB: C
    Julie Falardeau MD None
    Reviewers
    Shauna E Berry DO None
    Courtney E Francis MD None
    Susan M Ksiazek MD None
    Y Joyce Liao MD PhD None
    Nagham Al-Zubidi MD None

    Subcommittee for: Ocular Pathology, Oncology and Oculoplastics, Orbit

    Chair Disclosure
    Julian D Perry None
    Members
    Jonathan W Kim MD None
    Sara T Wester MD Horizon Therapeutics: C
    Reviewers
    Malena M Amato MD None
    Anne Barmettler MD None
    Steven M Couch MD None
    Michael K Yoon MD None
    Kenya M Williams MD None

    Subcommittee for: Pediatric Ophthalmology, Strabismus

    Chair Disclosure
    Martha P Schatz MD None
    Members
    Stacy L Pineles MD None
    Federico G Velez MD Luminopia: S; Nevakar: C; Novartis: C
    Reviewers
    Kara M Cavuoto MD None
    Sean P Donahue MD PhD Gensight: C; Olleyes: C
    Judith E Gurland MD None
    Tina Rutar MD Sydnexis: S, C
    Mitchell B Strominger MD None

    Subcommittee for: Refractive Surgery and Optics Refraction Contact Lenses

    Chair Disclosure
    Elizabeth Yeu MD Alcon Laboratories, Inc.: C,L; Allergan: C,L; ArcScan: C; Bausch + Lomb: C; Bausch Lomb: C; Bio-Tissue, Inc.: C,L; Carl Zeiss Meditec: C,L; Glaukos Corporation: C,L; nnovation Labs: O; iOptics: C,S; Johnson & Johnson Vision: C,L; Kala: C,S; Katena Products, Inc: C; Melt: C,O; Modernizing Medicine: O; Novartis, Alcon Pharmaceuticals: C; Ocular Science: C,O; OcuSoft: C; Omeros: L; ScienceBased Health: C; Sight Sciences: C; Sun Ophthalmics: L; Surface: C; Tarsus: C,O; TearLab: C; TearScience: C; TissueTech, Inc.: C,L; Topcon Medical Systems Inc.: S
    Members
    J Bradley Randleman MD None
    Edward E Manche MD Alcon Laboratories, Inc.: S; Allergan: S; Averdro: C,S; Best Doctors, Inc.: C; Carl Zeiss Inc: C,S; Guidepoint: C; Johnson & Johnson Vision: C,S; Novartis Pharma AG: S; Ocular Therapeutix: S; Placid0, INc: O; Presbia, Inc.: S; RxSight: O; Vacu-Site: O,P
    Reviewers
    Shamik Bafna MD AcuFocus, Inc.: C; Alcon Laboratories, Inc.: C; Beaver-Visitec International, Inc.: C; Carl Zeiss Meditec: C; CorneaGen: C; Ocular Therapeutix: S; RxSight: C; Sight Sciences, Inc.: C
    Brad E Kligman MD Dompe: S
    Kathryn Masselam Hatch MD Carl Zeiss Meditec: C; cxlo: C; EyePoint: C; EyeVance: C; Glaukos Corporation: C,O; Johnson & Johnson Vision: C; Sun Ophthalmics: C
    Jodhbir S Mehta MBBS PhD None
    Denise M Visco MD Bruder Healthcare Company: C; Carl Zeiss Inc: C,L; Cassini USA, Inc.: C; Eye Point Pharmaceuticals: C; LENSAR: C,L; Omeros: C,L; Sun Pharmaceuticals: C,L

    Subcommittee for: Retina, Vitreous and Uveitis, Intraocular Inflammation

    Chair Disclosure
    Sharon D Solomon MD None
    Members
    Anita Agarwal MD None
    Sunir J Garg MD FACS Allergan, Inc.: S; apellis: S; Bausch+Lomb: C; Boehringer Ingelheim: C,S; Johnson & Johnson: C; Nexttech: O; NGM Bio: S; Regeneron Pharmaceuticals, Inc.: S
    Reviewers
    Yannis Mantas Paulus MD Hedgefog Research Inc: C; PhotoSonoX LLC: P,O
    Roomasa Channa MD None
    Jay K Chhablani MBBS Abbvie: L; Allergan, Inc.: L; Biogen Inc: C; Novartis Pharma AG: C; Salutaris: C
    Adam S Wenick MD GENENTECH: C
    Alice Zhang MD None
    Jennifer E Thorne MD PhD AbbVie: C; Allergan: S; Clearside: C; Gilead Sciences: C; National Eye Institute: S; Santen: C
    John A Gonzales MD National Eye Institute: S
    Muge R Kesen MD None
    Jaclyn L Kovach MD Novartis Pharma AG: L; Regeneron Pharmaceuticals, Inc.: L
    Thomas A Albini MD Abbvie: C; Allergan: C; Bausch+Lomb: C; Clearside: C; GENENTECH: C; Mallinckrodt: C; Novartis, Alcon Pharmaceuticals: C; pSividia: C; Santen, Inc.: C

    Special Projects Committee

    The Special Projects Committee is responsible for developing programming and formats that cross subspecialties, as well as complement those that are submitted by members or societies.

    Associate Secretary Disclosure
    Florentino E Palmon MD None
    Members
    Daniel H Chang MD AcuFocus, Inc.: S; Allergan: C,S,L; Carl Zeiss Meditec: C,L; Johnson & Johnson Vision: C,L,S; Omega Ophthalmics: C,O
    Laura B Enyedi MD Novartis: C
    Collin M McClelland MD Horizon Therapeutics: C
    Carolyn K Pan MD None
    Rachel K Sobel MD Guidepoint: C
    Kateki Vinod MD None

    Skills Transfer Advisory Committee

    The Skills Transfer Advisory Committee is responsible for selecting the Skills Transfer courses and labs.

    Associate Secretary Disclosure
    Michael L Savitt MD None
    Members
    Brock K Bakewell MD Acufocus: S; Johnson & Johnson Vision: S
    Cat Burkat MD FACS None
    Clara C Chan MD Aequus: C; Allergan, Inc.: C,L,S; Bausch + Lomb: L,S; Johnson & Johnson Vision: C; Labtician Ophthalmics, Inc.: C; Novartis Pharma AG: C,S; Santen, Inc.: C; Sun Ophthalmics: C; TearLab Corporation: S; THEA: C,L; zeiss: C
    Brian A Francis MD None
    Anjali Tannan MD None
    Keye L Wong MD None

    2021 Subspecialty Day Advisory Committee

    Associate Secretary Disclosure
    R Michael Siatkowski MD National Eye Institute: S; OMIC-Ophthalmic Mutual Insurance Company: C
    Members
    Bonnie An Henderson MD Alcon Laboratories, Inc.: C,L
    Michael S Lee MD horizon: O; springer: P; sun biopharma: C; uptodate: P
    Jennifer Irene Lim MD Aldeyra Therapeutics: S; Allergan, Inc.: C; Aura Biosciences: C; Chengdu Kanghong: S; Cognition Therapeutics: C; CRC Press/ Taylor and Francis: P; Eyenuk: C; GENENTECH: C,S; Greybug: S; Iveric Bio: C; JAMA Ophthalmology Editorial Board: C; Luxa: C; NGM: S; Novartis Pharma AG: C; Ophthea: C; Quark: C; Regeneron Pharmaceuticals, Inc.: C,S; Santen, Inc.: C; Stealth: S; Unity: C; Viridian: C 
    Shahzad I Mian MD Centrasight: S; Kowa American Corporation: S; National Eye Institute: S
    Jody R Piltz MD Aerie Pharaceuticals: C,L,S

    2021 Subspecialty Day Program Directors

    Cornea

    Sophie X Deng MD PhD California Institute for Regenerative Medicine: S; Claris Biotherapeutics: C; Dompe Inc: C; Kowa Research Institute, Inc: C; National Eye Institute: S
    Vishal Jhanji MD None
    Sonal S Tuli MD None

    Glaucoma

    Brian A Francis MD None
    Kelly Walton Muir MD None

    Neuro-Ophthalmology

    Prem S Subramanian MD PhD GenSight Biologics: C,S; Horizon Pharmaceuticals: C,S; Invex Therapeutics: C; Santhera Pharmaceuticals: S; Viridian Therapeutics: C
    Peter A Quiros MD None

    Oculofacial Plastic Surgery

    Catherine J Hwang MD None
    Thomas Edward Johnson MD None

    Pediatric Ophthalmology

    David K Wallace MD MPH National Eye Institute: S
    Gena Heidary MD National Eye Institute: S

    Refractive Surgery

    Burkhard Dick MD Avedro, Inc.: C; Bausch + Lomb: L; Johnson & Johnson Vision: C; Johnson & Johnson: L; Oculus Surgical, Inc.: P; RxSight Inc.: C
    Deepinder K Dhaliwal MD Allergan, Inc.: C; Avedro, Inc.: S; Haag-Streit Group: C; Horizon: C; Johnson & Johnson: C; Novartis: C,S; Noveome: S; Ocular Therapeutix: L,C; STAAR Surgical: L; Trefoil: C

    Retina

    Mark W Johnson MD Amgen: C; Apellis: S; Aura Biosciences: C; Pfizer, Inc.: C
    Srinivas R Sadda MD 4DMT: C; Allergan: C; Amgen: C; Apellis: C; Astellas: C; Bayer Healthcare Pharmaceuticals: C; Carl Zeiss Meditec: C,L,S; Centervue: C; GENENTECH: C; Heidelberg Engineering: C,L,S; Iveric bio: C; Merck & Co., Inc.: C; Nidek: L; Novartis Pharma AG: C,L; Optos, Inc.: C; oxurion: C; Regeneron Pharmaceuticals, Inc.: C; Topcon Medical Systems Inc.: L

    AAOE Content Committee

    The AAOE Annual Meeting Program Committee is responsible for selecting the AAOE Instruction Courses, Coding Sessions and the Practice Management Master Classes.

    Chair Disclosure
    Natalie M Loyacano COMT ROUB OSA OCSR (F)ATPO None
    Members
    Stephanie Mangham Collins MBA COA OCSR Regeneron Pharmaceuticals, Inc.: C,L
    Lovell Davis MHA CPC CPB CRCS None
    Tori Elkins COT MBA None
    Brett D Gerwin MD None
    Anthony Pruett Johnson MD FACS None
    Bansari Mehta MHA None
    Christine M McDonald COE COA ROUB OSC CTC OCS None
    Heather Modjesky COE None

    Academy Staff

    Name Disclosure
    Debra Rosencrance None
    Melanie Rafaty None
    Sangeeta Fernandes None
    Susan Oslar None
    Ann L'Estrange None
    Elizabeth Washburn None
    Licia Wells None
    Julia Fennell None
    Sadie Peckens None